

Sjögren syndrome

Clio P. Mavragani MD, Haralampos M. Moutsopoulos MD

Sjögren syndrome is a chronic, systemic disorder of an autoimmune nature. It is characterized by lymphocytic infiltration of the exocrine (mainly salivary and lacrimal) glands and by remarkable B-cell hyperactivity. The latter is manifested by hypergammaglobulinemia and the presence of serum autoantibodies, including antinuclear antibodies, rheumatoid factor, cryoprecipitable immunoglobulins and antibodies against two ribonucleoproteic complexes named Ro/SSA and La/SSB; these antibodies are considered hallmarks of the disease.^{1,2} Although their exact role is not known, recent data suggest that antibodies against the Ro52 component of the Ro/SSA antigen (a 52kD protein that inhibits proinflammatory responses) might inhibit its regulatory function.³ The condition is nine times more common among women than among men, with peak onset during menopause.¹ A recent review suggests that the prevalence ranges from 0.1% to 4.8%,¹ with rates increasing with advanced age.^{4,5} Heterogeneity in inclusion criteria, ethnic origin, sample size and sex distribution between studies contributed to the observed variability.

Although Sjögren syndrome is classically considered to be localized disease of the exocrine glands, mainly manifested with oral and ocular dryness, it also has a wide range of systemic clinical manifestations that affect essentially any organ system, and a small number of cases are complicated by the development of non-Hodgkin lymphoma.^{1,6} Secondary Sjögren syndrome is associated with an established connective-tissue disease.

As is the case for many autoimmune diseases, the primary etiopathogenetic events are not

known. The current hypothesis is that an interplay between environmental contributors (e.g., viruses, stress, hormones) and the patient's genetic background can lead to inflammatory responses against epithelial tissues. In this review, we summarize the current evidence, mostly from observational, open-label and randomized clinical trials, for the clinical manifestations, diagnosis and management of Sjögren syndrome (Box 1).

What are the clinical features of Sjögren syndrome?

The clinical features of Sjögren syndrome can be largely divided into those related to exocrine dysfunction (glandular) and those that affect organs other than the exocrine glands (extraglandular or systemic). The latter can be further divided into nonspecific features, those characterized by periepithelial infiltrates in parenchymal organs and those that result from immunocomplex deposition as a result of B-cell hyperactivity.^{7,8} Most patients with Sjögren syndrome (about 90%) have an indolent benign course; however, a small but important number of cases (5%–10%) are complicated by immunocomplex pathology and lymphoid neoplasia, both of which are associated with high mortality (a 3.25-fold increase compared with the general population).^{6,7,9}

Competing interests: None declared.

This article has been peer reviewed.

Correspondence to: Haralampos Moutsopoulos, hmoutsop@med.uoa.gr

CMAJ 2014; DOI:10.1503/cmaj.122037

Box 1: Evidence used in this review

Using the MeSH term "Sjögren syndrome," we searched MEDLINE for randomized controlled trials, systematic reviews and observational studies involving adult humans. We included studies published in English between Jan. 1, 1975, and Nov. 25, 2012. We also manually searched the reference lists of relevant articles retrieved.

KEY POINTS

- Sjögren syndrome is a chronic autoimmune disease that mainly affects middle-aged women.
- Clinical manifestations are mainly classified as glandular (manifested mainly by dry eyes and mouth) or extraglandular (systemic).
- About 5%–10% of cases are complicated by the development of lymphoma.
- Diagnosis is made by observing ocular and oral dryness, by measuring serum autoantibody levels and by observing periductal lymphocyte infiltration in salivary gland biopsy samples.
- Local measures and cholinergic agents are the main therapeutic methods used to alleviate oral and ocular dryness. B-cell targeted therapies are reserved for the systemic manifestations of the syndrome.

The main features of glandular and extraglandular manifestations in Sjögren syndrome are shown in Table 1.^{6,7,9-40} Besides sicca features, easy fatigability is one of the most frequent symptoms, occurring in 70% of patients with primary Sjögren

syndrome; these patients typically report functional disability and an increased need for rest.^{13,26,41} Patients with primary Sjögren syndrome may show several psychopathologic features depending on premorbid personality traits and in

Table 1 (part 1 of 2): Clinical manifestations of primary Sjögren syndrome

Clinical manifestation	Prevalence, %	Clinical and laboratory features
Glandular¹⁰		
Oral dryness ⁷	90	• Destruction of the glandular epithelium, antibodies against muscarinic receptors, impairment of neurotransmission • Difficulty chewing or swallowing, sore mouth • Oral infections and dental caries, fungal infections (pseudomembranous or erythematous mucosal lesions, fissured tongue, atrophy of filiform papillae and angular cheilitis)
Parotid gland enlargement ⁷	50	• Usually bilateral, firm to palpation, asymptomatic, adverse predictor of lymphoma
Ocular dryness ⁷	95	• Sandy feeling or itchiness of the eyes • Reduced tear secretion, chronic irritation and destruction of the corneal and bulbar conjunctival epithelium (keratoconjunctivitis sicca)
Dry skin	~10	• Dry skin with accompanying pruritus
Dryness of the upper respiratory tract ⁷	20	• Dry nasal mucosa, xerotrachea, bronchitis sicca • Chronic dry cough, shortness of breath (xerotrachea/bronchitis sicca)
Dyspareunia ¹¹	40	• Dyspareunia commonly observed in premenopausal women (dysfunction of lubricative vaginal glands)
Extraglandular (systemic)		
Nonspecific		
Musculoskeletal ⁷	70	• Jaccoud arthropathy (reversible hand deformities, absence of erosive lesions);^{7,25,26} radiographs of the hands show soft-tissue calcification (especially in association with Raynaud phenomenon)¹²
Raynaud phenomenon ¹²	30	• Milder in Sjögren syndrome compared with other autoimmune diseases; no associated vascular complications^{12,27,28}
Fatigue ¹³	70	• Increase demand for rest, associated with functional disability
Periepithelial		
Bronchial ⁷	20	• Peribronchial and/or peribronchiolar mononuclear inflammation • Dry cough and shortness of breath on exertion • Pulmonary function testing: predominantly small airway obstructive pattern • Chest radiography: usually normal or ill-defined pattern of infiltrates • High-resolution computed tomography: thickened bronchial walls; pure interstitial involvement is less frequent (common types: lymphocytic interstitial pneumonia characterized by thin wall cysts on imaging, lymphocytic bronchiolitis^{29,30})
Liver		• Lymphocytic infiltration around cholangial cells
Hepatomegaly ¹⁴	25	• Antimitochondrial antibodies and Sjögren syndrome: two-thirds of patients show liver enzyme abnormalities
Presence of antimitochondrial antibodies ¹⁴	5	• Liver histopathology: mild intrahepatic bile duct inflammation reminiscent of primary biliary cirrhosis (stage I)¹⁴ • Progression of Sjögren syndrome-associated primary biliary cirrhosis: very slow in clinical, serologic and histopathologic terms³¹
Kidney ¹⁵	2.5	• Interstitial nephritis-lymphocytic infiltration around renal tubular cells • Subclinical course • Distal renal tubular acidosis (hypokalemia, low specific gravity and alkaline pH of the urine, nephrocalcinosis)^{15,32,33} • Mild chronic renal compromise³⁴

continued

association with antibodies against neuropeptides.⁴² Increased rates of neuroticism, psychotism, obsessiveness, hypochondriasis, paranoid ideation, somatization, obsessive-compulsive symptoms, sleep disturbances and defective coping strategies have been reported.^{7,43–47}

Non-Hodgkin lymphoma is a well-recognized complication of Sjögren syndrome.^{6,39} Peripheral neuropathy, glomerulonephritis, lymphopenia,

vasculitis or purpuric lesions, low C4 levels, cryoglobulinemia and the presence of germinal centres in salivary gland biopsy samples are well-recognized adverse predictors of lymphoma.^{7,9,39,40} In a comparative analysis involving patients with mucosa-associated lymphoid tissue lymphoma with or without underlying autoimmune disease, there were no differences in the rate of relapse, time to relapse or survival.⁴⁸

Table 1 (part 2 of 2): Clinical manifestations of primary Sjögren syndrome

Clinical manifestation	Prevalence, %	Clinical and laboratory features
Endocrine glands		• Periepithelial lymphocytic infiltrations in thyroid, adrenals, ovaries
<u>Autoimmune thyroid disease</u>		• Suggests a subtype of Sjögren syndrome with a mild course and C4 normocomplementemia³⁵
Antibodies to thyroid antigens ¹⁶	10–20	
Clinical hypothyroidism ¹⁶	1.5–16.5	
<u>Autoimmune adrenal disease</u>		
Antibodies to adrenal antigens (21 hydroxylase) ¹⁷	17	• Associated with B-cell activating cytokines and adrenal hyporesponsiveness
Overt adrenal failure ¹⁷	0	
<u>Autoimmune ovarian disease</u>		
Antibodies to ovarian antigens ¹⁸	27	
Immunocomplex-associated disease		• Deposition of immunocomplexes in small vessels of the skin, nerves, kidney, brain as a result of B-cell hyperactivity
<u>Cutaneous vasculitis</u> ^{7,19,20}		
Palpable purpura ⁷	10	• Most common manifestation of cutaneous vasculitis • Associated with hypocomplementemia and cryoglobulinemia conferring increased risk of lymphoma • Flat purpura can also occur in the setting of hypergammaglobulinemia
<u>Peripheral neuropathy</u> ^{21,22}	2–10	
Sensory axonal neuropathy		• Glove–stocking distribution
Small fibre neuropathy		• Painful or burning paresthesia
Sensorimotor neuropathy		• Adverse predictor of lymphoma in association with hypocomplementemia, cryoglobulinemia and vasculitic lesions
<u>Glomerulonephritis</u> ¹⁵	~2	• Associated with systemic vasculitis, hypocomplementemia and cryoglobulinemia; adverse predictor of lymphoma and survival • Membranoproliferative and membranous glomerulonephritis are the most commonly occurring histopathologic types • Immunofluorescence showing IgM and complement deposition in renal tissues; hypertension, mild proteinuria and hematuria are the most common manifestations³⁶
<u>Central nervous system vasculopathy</u> ^{23,24}	3–20	• Associated with antibodies against SSA (Ro/SSA) • Multiple sclerosis-like features^{24,37} • Antibodies against aquaporin-4 have been detected among patients with lupus and Sjögren syndrome with evidence of longitudinally extensive transverse myelitis or optic neuritis³⁸
Lymphoma ⁶	5–10	• Chronic antigenic stimulation, genetic aberrations • Sites of involvement include minor and/or major salivary glands, stomach, lungs, nodes; involvement of bone marrow is rare • Adverse predictors of lymphoma include peripheral neuropathy, glomerulonephritis, lymphopenia, vasculitic or purpuric lesions, low C4 levels, cryoglobulinemia, germinal centres in salivary gland biopsy^{7,9,39,40}
Mucosa-associated lymphoid tissue (most common); nodal marginal zone lymphoma; diffuse large B-cell lymphoma		

How should a diagnosis of Sjögren syndrome be made?

The key to prompt diagnosis is clinical evaluation for every patient who presents with symptoms of oral or ocular dryness. This evaluation should include a complete systems review, including specific questions to assess oral and ocular dryness, clinical examination and investigations to assess the degree of exocrine gland dysfunction, the presence of relevant immunologic abnormalities and the extent of organ involvement. Because sicca symptomatology can be attributed to several different clinical entities, the differential diagnosis is extensive (Box 2).^{26,49–51} In a prospective multicentre trial, the prevalence of Sjögren syndrome in a cohort of patients with clinically important aqueous-deficient dry eye was 11.6%.⁵² In contrast, in a closed rural community, about 15% of patients ($n = 35$) with sicca symptoms who underwent full evaluation for Sjögren syndrome fulfilled the classification criteria for the diagnosis.⁵³

In clinical practice, patients who present with sicca symptoms should be offered assessment of lacrimal gland function (measuring tear production using Schirmer test [wetting on a paper strip of ≤ 5 mm in 5 min]; sensitivity 76.9%; specificity 4%–72%) and examination of the cornea and conjunctiva using rose bengal or lissamine green stain (reveals punctuate or filamentary keratitis lesions, typical of keratoconjunctivitis sicca; sensitivity 64.3%; specificity 81.7%). Unstimulated saliva secretion should also be measured (in a graded tube; > 1.5 mL in 15 min is considered normal; sensitivity 56.1%; specificity 80.7%). A biopsy of a minor salivary gland should be performed to assess the presence of lymphocytic infiltrates around salivary gland epithelium (hallmark of Sjögren syndrome; sensitivity 82.4%; specificity 86.2%).⁵⁴ An average focus score of 1 or greater in the salivary

gland biopsy sample is considered indicative of Sjögren syndrome. The focus score is calculated as the number of lymphocyte foci per 4-mm^2 surface based on a survey of at least four lobules. A focus is a cluster of at least 50 lymphocytes.⁵⁵

Other investigations include a full blood count, chemistry panel, chest radiography, protein electrophoresis, testing for antinuclear antibodies, antibodies against Ro/SSA and La/SSB autoantigens and rheumatoid factor, and viral testing for hepatitis C virus, HIV and human T-lymphotropic virus 1. Antibodies against thyroid antigens and thyroid function should be evaluated, given the association between autoimmune thyroid disease and sicca complaints.⁵⁰ Antibodies against Ro/SSA can be detected in 70%–100% of patients with Sjögren syndrome; La/SSB antibodies can be detected in 35%–70%. Antibodies against La/SSB are considered to be a highly specific diagnostic marker for Sjögren syndrome.^{3,56} According to the classification criteria, the presence of these antibodies along with other features suggestive of Sjögren syndrome is sufficient for establishing the diagnosis, even in the absence of a positive salivary gland biopsy.⁵⁷

Once the diagnosis is established, additional investigational tests (e.g., cryoglobulins, complement levels, immunofixation) should also be offered, particularly to patients with peripheral purpura, peripheral neuropathy, salivary gland enlargement or in situ demonstration of salivary gland lymphoma. Upper endoscopy, bone marrow biopsy and computed tomography scans of the neck, thorax and abdomen should be performed to detect the potential development and extent of lymphoma.

To aid in the classification of Sjögren syndrome, the international research community proposed the American–European Consensus Criteria for Sjögren's Syndrome (Box 3), which require the presence of either focal lymphocytic infiltrates in minor salivary glands with a focus score of 1 or more, or the presence of SSA or SSB autoantibodies along with features suggestive of salivary or lacrimal gland involvement.⁵⁷ A new set of preliminary criteria was recently proposed by the American College of Rheumatology; these criteria are based solely on objective criteria⁵⁸ (Box 3).

Box 2: Differential diagnosis of Sjögren syndrome^{26,49–51}

- Medications (e.g., diuretics, antihistamines)
- Viral infections (e.g., HIV infection, hepatitis C virus infection)
- Tumours (e.g., parotid gland tumour)
- Metabolic disorders (diabetes mellitus, lipoproteinemia types II, IV and V)
- Irradiation
- Sarcoidosis
- Chronic graft-versus-host disease
- Lymphoma
- Amyloidosis
- IgG4-related sialadenitis
- Autoimmune thyroid disease

What therapies are effective for mucosal dryness in Sjögren syndrome?

The treatment of mucosal dryness related to Sjögren syndrome is mainly intended to alleviate symptoms and prevent complications such as dental caries, dysphagia and oral candidiasis. As general measures, alcohol, smoking and medications such as diuretics, antidepressants (with the excep-

tion of selective serotonin reuptake inhibitors, especially escitalopram and fluoxetine) and antihistamines should be avoided because they exacerbate mucosal dryness; air conditioning should also be avoided. Mouth hygiene, thorough dental follow-up, stimulation of salivary flow (sugar-free gum or citrus juice) and administration of saliva substitutes are generally advised for the management of oral dryness.⁵⁹ Salivary substitutes have been shown to improve subjective symptoms of oral dryness (e.g., burning mouth, difficulties with mastication and swallowing) without affecting the rate of salivary output.⁶⁰ Painful enlargement of salivary glands can be alleviated by local application of moist heat and administration of non-

steroidal anti-inflammatory drugs after bacterial infection and lymphoma have been ruled out.

Ocular dryness should initially be treated with preservative-free teardrops or eye lubricants containing either sodium hyaluronate or hydroxypropyl methylcellulose, which improve both subjective symptoms and objective signs of ocular dryness (e.g., Schirmer test, rose bengal staining, impression cytology scores).^{61–64} In cases of moderate to severe dry eye disease, cyclosporine drops (0.05%) for six months were shown to lead to remarkable improvement in Schirmer test and corneal staining scores and subjective ocular symptoms (e.g., reduced blurred vision, use of artificial tears).⁶⁵

Box 3: Classification criteria for Sjögren syndrome

American/European classification criteria⁵⁷

Ocular symptoms (at least one)

- Persistent, troublesome dry eyes every day for longer than three months
- Recurrent sensation of sand or gravel in the eyes
- Use of a tear substitute more than three times per day

Oral symptoms (at least one)

- Feeling of dry mouth every day for at least three months
- Recurrent feeling of swollen salivary glands as an adult
- Need to drink liquids to aid in swallowing dry foods

Objective evidence of dry eyes (at least one)

- Schirmer test ≤ 5 mm/5min
- Van Bijsterveld score ≥ 4 (after lissamine test)

Objective evidence of salivary-gland involvement (at least one)

- Salivary-gland scintigraphy
- Parotid sialography
- Unstimulated salivary flow (≤ 1.5 mL/15 min, ≤ 0.1 mL/min)

Histological features

- Positive biopsy sample of a minor salivary gland (focus score > 1 ; refers to a cluster of ≥ 50 lymphocytes per lobule when at least four lobules are assessed)

Autoantibodies

- Presence of antibodies to SSA (Ro/SSA) or to SSB (La/SSB)

Classification

- Primary Sjögren syndrome requires the presence of four of six criteria, including a positive biopsy sample of a minor salivary gland or antibodies against SSA or SSB, or three of the four objective criteria
- Secondary Sjögren syndrome requires an established connective-tissue disease and one sicca symptom plus any three of the four objective criteria
- Exclusions: previous radiotherapy to the head and neck, lymphoma, sarcoidosis, graft-versus-host disease, infection with hepatitis C virus or HIV, or the use of anticholinergic drugs

American College of Rheumatology criteria⁵⁸

- Antibodies against SSA (Ro/SSA) or SSB (La/SSB), or positive rheumatoid factor and antinuclear antibody levels of 1:320 or greater
- Labial salivary gland biopsy showing focal lymphocytic sialadenitis with a focus score ≥ 1 focus/4 mm²
- Keratoconjunctivitis sicca with ocular staining score ≥ 3 (assumes that the patient is not currently using daily eye drops for glaucoma and has not had corneal surgery or cosmetic eyelid surgery in the last five yr)
- Classification of Sjögren syndrome, which applies to patients with signs or symptoms suggestive of Sjögren syndrome, requires the presence of at least two of the three aforementioned objective features.
- Exclusions: history of head and neck radiation treatment, infection with hepatitis C virus, AIDS, sarcoidosis, amyloidosis, graft-versus-host disease or IgG4-related disease

Among patients with residual gland function, the beneficial use of two cholinergic agents was shown in controlled studies. Patients who used pilocarpine (10–30 mg once daily) showed statistically significant improvements in dryness (oral, ocular, nasal, vaginal, skin) and salivary flow rates. Cevimeline use (30 mg three times daily) has been also associated with improved subjective oral and ocular symptoms, increased salivary flow rates and objective ocular signs.⁶⁶ Although steroid-containing ophthalmic solutions have shown short-term benefits, caution should be taken with prolonged use because serious adverse effects (e.g., raised intraocular pressure, worsening or development of cataracts, impaired corneal wound healing, increased risk of infection risk) may occur.^{66–69} Women with vaginal dryness and dyspareunia may benefit from vaginal lubricants, as suggested by studies not focused on Sjögren syndrome.⁷⁰ In patients with earlier disease onset and preserved salivary function, improvements have been shown using both subjective (visual analog scale [VAS] scores for sicca symptoms) and objective measures after treatment with rituximab (monoclonal antibody against CD20).⁷¹

What therapies are effective for the management of systemic features in Sjögren syndrome?

Systemic therapy should be considered for patients showing systemic features and should be tailored to the organs affected and to the severity. Because of a lack of robust data from controlled studies, the management of extraglandular manifestations is mainly based on case-series reports, open-label studies and expert opinion based on biological rationale and experience with other autoimmune diseases. Therapeutic options for the systemic manifestations of Sjögren syndrome are shown in Table 2.^{59,66,72,73}

In patients for whom arthralgia or myalgia is the predominant symptom, hydroxychloroquine therapy has been shown to improve arthralgia, myalgia and joint inflammation; methotrexate can be used in cases of inflammatory arthritis.^{72,74} For cases of persistent arthritis, rituximab has been shown to significantly improve the tender and swollen joint count.⁷⁵ A pilot open-label study reported that weekly administration of methotrexate to patients

Table 2: Therapeutic options for systemic features in Sjögren syndrome^{59,66,72,73}

Feature	Therapy
Nonspecific symptoms	
Fatigue	• Antidepressants, exercise
Raynaud phenomenon	• Avoidance of cold and stress; calcium-channel blockers
Arthralgia, arthritis	• Nonsteroidal anti-inflammatory drugs, hydroxychloroquine, methotrexate
Periepithelial involvement	
Interstitial nephritis-tubular dysfunction, renal tubular acidosis	• Oral potassium and sodium carbonate
Bronchial or bronchiolar involvement	• Inhaled therapy
Interstitial lung disease	• Prednisolone, azathioprine
Primary biliary cirrhosis	• Ursodeoxycholic acid
Autoimmune hepatitis	• Prednisolone, azathioprine
Immunocomplex-associated disease	
Peripheral neuropathy	• Intravenous gamma globulin • Rituximab • Plasma exchange
Vasculitis	• Prednisolone • Cyclophosphamide • Rituximab • Plasmapheresis
Glomerulonephritis	• Prednisolone, intravenous cyclophosphamide
Central nervous system disease	• Pulse steroids • Prednisolone • Cyclophosphamide • Azathioprine

with Sjögren syndrome reduced the frequency of parotid gland enlargement, dry cough and purpura.⁷⁶ In patients with primary Sjögren syndrome, blockade of tumor necrosis factor α (infliximab and etanercept) does not appear to be effective in reducing subjective and objective measures of salivary and lacrimal function or joint inflammation; augmentation of the already activated type I interferon/B-cell activating factor (BAFF) axis has been suggested to account for this failure.^{77,78}

Cytotoxic drugs (e.g., cyclophosphamide) are reserved for severe extraglandular manifestations, including cutaneous vasculitis and glomerulonephritis. Given that B-cell activation is a disease cornerstone, choosing targeted therapies against B cells is a logical approach.^{6,72} Improvement in fatigue scores in a randomized controlled trial and demonstrated efficacy in extraglandular features (e.g., cryoglobulinemic vasculitis) and peripheral neuropathy with reduction of disease activity indices imply that rituximab is a promising therapeutic strategy for Sjögren syndrome.^{73,75,79–82}

Unanswered questions

Key questions remain with regard to disease pathogenesis, clinical spectrum and therapeutic strategies. Four main questions are the focus of basic and clinical research: the identification of proximal triggers (exogenous or endogenous factors) that account for epithelial activation and immunological injury; the thorough characterization of various clinical phenotypes and association with distinct pathogenetic pathways such as type I interferon/BAFF axis—designation of tailored therapies; determination of the underlying genetic, epigenetic and immunologic mechanisms of lymphomagenesis related to Sjögren syndrome; and the implementation of preventative therapeutic strategies against lymphoma development in high-risk patients with Sjögren syndrome.

References

- Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren's syndrome. *Autoimmun Rev* 2010;9:A305-10.
- Routsias JG, Tzioufas AG. Autoimmune response and target autoantigens in Sjögren's syndrome. *Eur J Clin Invest* 2010;40:1026-36.
- Yoshimi R, Ueda A, Ozato K, et al. Clinical and pathological roles of Ro/SSA autoantibody system. *Clin Dev Immunol*. 2012; 2012:606195.
- Drosos AA, Andonopoulos AP, Costopoulos JS, et al. Prevalence of primary Sjögren's syndrome in an elderly population. *Br J Rheumatol* 1988;27:123-7.
- Haugen AJ, Peen E, Hulten B, et al. Estimation of the prevalence of primary Sjögren's syndrome in two age-different community-based populations using two sets of classification criteria: the Hordaland Health Study. *Scand J Rheumatol* 2008;37:30-4.
- Voulgarelis M, Ziakas PD, Papageorgiou A, et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. *Medicine (Baltimore)* 2012;91:1-9.
- Skopouli FN, Dafni U, Ioannidis JP, et al. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. *Semin Arthritis Rheum* 2000;29:296-304.
- Malladi AS, Sack KE, Shiboski S, et al. Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry. *Arthritis Care Res (Hoboken)*. 2012; 64:911-8.
- Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. *Arthritis Rheum* 2002; 46:741-7.
- Sumida T, Tsuboi H, Iizuka M, et al. Anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome. *Mod Rheumatol* 2013;23:841-5.
- Skopouli FN, Papanikolaou S, Malamou-Mitsi V, et al. Obstetric and gynaecological profile in patients with primary Sjögren's syndrome. *Ann Rheum Dis* 1994;53:569-73.
- Skopouli FN, Talal A, Galanopoulou V, et al. Raynaud's phenomenon in primary Sjögren's syndrome. *J Rheumatol* 1990;17:618-20.
- Ng WF, Bowman SJ. Primary Sjögren's syndrome: too dry and too tired. *Rheumatology (Oxford)* 2010;49:844-53.
- Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren's syndrome. *Br J Rheumatol* 1994;33:745-8.
- Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. *Medicine (Baltimore)* 2000;79:241-9.
- Mavragani CP, Fragoulis GE, Moutsopoulos HM. Endocrine alterations in primary Sjögren's syndrome: an overview. *J Autoimmun* 2012;39:354-8.
- Mavragani CP, Schini M, Gravani F, et al. Brief report: adrenal autoimmunity in primary Sjögren's syndrome. *Arthritis Rheum* 2012;64:4066-71.
- Euthymiopoulou K, Aletras AJ, Ravazoula P, et al. Antiovarian antibodies in primary Sjögren's syndrome. *Rheumatol Int* 2007; 27:1149-55.
- Tsokos M, Lazarou SA, Moutsopoulos HM. Vasculitis in primary Sjögren's syndrome. Histologic classification and clinical presentation. *Am J Clin Pathol* 1987;88:26-31.
- Ramos-Casals M, Anaya JM, Garcia-Carrasco M, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. *Medicine (Baltimore)* 2004;83:96-106.
- Brito-Zerón P, Akasbi M, Bosch X, et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren's syndrome. *Clin Exp Rheumatol* 2013;31:103-10.
- Pavakis PP, Alexopoulos H, Kosmidis ML, et al. Peripheral neuropathies in Sjögren syndrome: a new reappraisal. *J Neurol Neurosurg Psychiatry* 2011;82:798-802.
- Alexander EL, Arnett FC, Provost TT, et al. Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. *Ann Intern Med* 1983;98:155-9.
- Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvement in Sjögren's syndrome. *Ann Rheum Dis* 2004; 63:616-20.
- Tsmpoulas CG, Skopouli FN, Sartoris DJ, et al. Hand radiographic changes in patients with primary and secondary Sjögren's syndrome. *Scand J Rheumatol* 1986;15:333-9.
- Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. *Arch Intern Med* 2004; 164:1275-84.
- Youniou P, Pennec YL, Katsikis P, et al. Raynaud's phenomenon in primary Sjögren's syndrome. *Br J Rheumatol* 1990;29:205-7.
- García-Carrasco M, Siso A, Ramos-Casals M, et al. Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. *J Rheumatol* 2002; 29:726-30.
- Papiris SA, Maniati M, Constantopoulos SH, et al. Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. *Ann Rheum Dis* 1999;58:61-4.
- Papiris SA, Tsonis IA, Moutsopoulos HM. Sjögren's syndrome. *Semin Respir Crit Care Med* 2007;28:459-71.
- Hatzis GS, Fragoulis GE, Karatzafiris A, et al. Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren's syndrome. *J Rheumatol* 2008;35:2012-6.
- Maripuri S, Grande JP, Osborn TG, et al. Renal involvement in primary Sjögren's syndrome: a clinicopathologic study. *Clin J Am Soc Nephrol* 2009;4:1423-31.
- Moutsopoulos HM, Cledes J, Skopouli FN, et al. Nephrocalcinosis in Sjögren's syndrome: a late sequela of renal tubular acidosis. *J Intern Med* 1991;230:187-91.
- Goules AV, Tatouli IP, Moutsopoulos HM, et al. Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome. *Arthritis Rheum* 2013;65:2945-53.
- Caramaschi P, Biasi D, Caimmi C, et al. The co-occurrence of Hashimoto thyroiditis in primary Sjögren's syndrome defines a subset of patients with milder clinical phenotype. *Rheumatol Int* 2013;33:1271-5.

36. Moutsopoulos HM, Balow JE, Lawley TJ, et al. Immune complex glomerulonephritis in sicca syndrome. *Am J Med* 1978;64:955-60.
37. Alexander EL. Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis. *Rheum Dis Clin North Am* 1993;19:869-908.
38. Wandinger KP, Stangel M, Witte T, et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome. *Arthritis Rheum* 2010;62:1198-200.
39. Baimpa E, Dahabreh IJ, Voulgarelis M, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. *Medicine (Baltimore)* 2009;88:284-93.
40. Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. *Ann Rheum Dis* 2011;70:1363-8.
41. Hackett KL, Newton JL, Frith J, et al. Impaired functional status in primary Sjögren's syndrome. *Arthritis Care Res (Hoboken)* 2012; 64:1760-4.
42. Karaiskos D, Mavragani CP, Sinno MH, et al. Psychopathological and personality features in primary Sjögren's syndrome—associations with autoantibodies to neuropeptides. *Rheumatology (Oxford)* 2010;49:1762-9.
43. Drosos AA, Angelopoulos NV, Liakos A, et al. Personality structure disturbances and psychiatric manifestations in primary Sjögren's syndrome. *J Autoimmun* 1989;2:489-93.
44. Strömbeck B, Theander E, Jacobsson LT. Assessment of fatigue in primary Sjögren's syndrome: the Swedish version of the Profile of Fatigue. *Scand J Rheumatol* 2005;34:455-9.
45. Theander L, Strömbeck B, Mandl T, et al. Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sjögren's syndrome? *Rheumatology (Oxford)* 2010;49:1177-83.
46. Gudbjörnsson B, Broman JE, Hetta J, et al. Sleep disturbances in patients with primary Sjögren's syndrome. *Br J Rheumatol* 1993;32:1072-6.
47. Karaiskos D, Mavragani CP, Makaroni S, et al. Stress, coping strategies and social support in patients with primary Sjögren's syndrome prior to disease onset: a retrospective case-control study. *Ann Rheum Dis* 2009;68:40-6.
48. Wöhrer S, Troch M, Streubel B, et al. MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. *Leukemia* 2007;21:1812-8.
49. Nocturne G, Pavy S, Lazure T, et al. IgG4 multiorgan lymphoproliferative syndrome as a differential diagnosis of primary Sjögren's syndrome in men? *Ann Rheum Dis* 2011;70:2234-5.
50. Mavragani CP, Skopouli FN, Moutsopoulos HM. Increased prevalence of antibodies to thyroid peroxidase in dry eyes and mouth syndrome or sicca asthenia polyalgia syndrome. *J Rheumatol* 2009;36:1626-30.
51. Mavragani CP, Fragoulis GE, Rontogianni D, et al. Elevated IgG serum levels among primary Sjögren's syndrome patients: Do they unmask underlying IgG4-Related disease? *Arthritis Care Res.* 2013 DOI: 10.1002/acr.22216.
52. Liew MS, Zhang M, Kim E, et al. Prevalence and predictors of Sjögren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. *Br J Ophthalmol* 2012;96:1498-503.
53. Dafni UG, Tzioufas AG, Staikos P, et al. Prevalence of Sjögren's syndrome in a closed rural community. *Ann Rheum Dis* 1997;56: 521-5.
54. Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. *Ann Rheum Dis* 1994;53:637-47.
55. Stewart CM, Bhattacharyya I, Berg K, et al. Labial salivary gland biopsies in Sjögren's syndrome: still the gold standard? *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008;106:392-402.
56. Venables PJ, Shattles W, Pease CT, et al. Anti-La (SS-B): A diagnostic criterion for Sjögren's syndrome? *Clin Exp Rheumatol* 1989;7:181-4.
57. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002;61:554-8.
58. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. *Arthritis Care Res (Hoboken)* 2012;64:475-87.
59. Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjögren's syndrome. *Clin Rev Allergy Immunol* 2007;32:284-91.
60. Alves MB, Motta AC, Messina WC, et al. Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial. *Quintessence Int* 2004;35:392-6.
61. Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. *Br J Ophthalmol* 2002;86:181-4.
62. Condon PI, McEwen CG, Wright M, et al. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. *Br J Ophthalmol* 1999;83:1121-4.
63. McDonald CC, Kaye SB, Figueiredo FC, et al. A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. *Eye (Lond)* 2002;16:601-7.
64. Toda I, Shinozaki N, Tsubota K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren's syndrome. *Cornea* 1996;15:120-8.
65. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. *Ophthalmology* 2000;107:631-9.
66. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. *JAMA* 2010; 304:452-60.
67. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. *Ophthalmology* 1999;106:811-6.
68. Hersh PS, Rice BA, Baer JC, et al. Topical nonsteroidal agents and corneal wound healing. *Arch Ophthalmol* 1990;108:577-83.
69. Vivino FB, Minerva P, Huang CH, et al. Corneal melt as the initial presentation of primary Sjögren's syndrome. *J Rheumatol* 2001;28:379-82.
70. Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. *Obstet Gynecol* 1998;92:722-7.
71. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2010;62:960-8.
72. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. *Nat Clin Pract Rheumatol* 2006;2:252-61.
73. Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome. *Nat Rev Rheumatol* 2012;8:399-411.
74. Fox RI, Dixon R, Guarrasi V, et al. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. *Lupus* 1996;5(Suppl 1):S31-6.
75. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. *Ann Rheum Dis* 2013;72:1026-31.
76. Skopouli FN, Jagiello P, Tsifetaki N, et al. Methotrexate in primary Sjögren's syndrome. *Clin Exp Rheumatol* 1996;14:555-8.
77. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). *Arthritis Rheum* 2004;50:1270-6.
78. Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. *Arthritis Rheum* 2007;56:3995-4004.
79. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. *Ann Rheum Dis* 2008;67:1541-4.
80. Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry. *Ann Rheum Dis* 2012; 71:84-7.
81. Mariette X, Gottenberg JE. Pathogenesis of Sjögren's syndrome and therapeutic consequences. *Curr Opin Rheumatol* 2010;22: 471-7.
82. Seror R, Sordet C, Guillemin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. *Ann Rheum Dis* 2007;66:351-7.

Affiliations: Departments of Physiology (Mavragani) and Pathophysiology (Moutsopoulos), Faculty of Medicine, University of Athens, Athens, Greece

Contributors: Clio Mavragani drafted the manuscript and Haralampos Moutsopoulos critically revised it. Both authors contributed to data collection and approved the final version.